Tandem Diabetes' New Tech Is Cool, but It Will Face a Crowded Market
The impressive headlines were enough to grab investors' attention last week. Not only did Tandem Diabetes (NASDAQ: TNDM) win the U.S. Food and Drug Administration's clearance of its new insulin pump management platform, but it even spurred the FDA's creation of a whole new category of insulin-dosing technology. The Control-IQ technology is a complete automated insulin dosing (AID) system that offers interoperability with other manufacturers' insulin monitoring devices. In this case, Control-IQ works with Dexcom's (NASDAQ: DXCM) G6 continuous glucose monitoring tool. Other diabetes-management tech companies could make compatible devices in the future.
The rub is that rivals are already nipping at Tandem's heels. In fact, a sizable piece of the insulin-dosing market is rooted in open-source options and do-it-yourself solutions that make a diabetic's smartphone the centerpiece of their self-management effort.
Image Source: Getty Images.
Source Fool.com
